Kyverna Therapeutics, Inc. KYTX
6.81
(0.18)
(2.58%)
as of 25 Sep
- Market cap
- $432.3M
- P/E
- 0.0×
Follow KYTX
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
9.06 | 8.15 | 7.75 | 5.16 |
+8 more quarters Free account |
Net Debt/EBITDA |
4.46 | 5.16 | 6.54 | 4.47 | |
Debt/Assets |
11.32% | 9.65% | 8.42% | 0.00% | |
Debt/Equity |
0.15 | 0.13 | 0.11 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.05 | 1.05 | 0.89 | 1.18 | |
Capex/Depreciation |
(0.68) | 0.00 | 0.00 | 0.16 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.67) | (0.69) | (0.76) | (1.00) | |
Cash per Share |
3.27 | 3.91 | 6.31 | 3.94 | |
Shareholders Equity per Share |
2.72 | 3.24 | 5.25 | 3.50 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.72 | 3.24 | 5.25 | 3.50 | |
Free Cash Flow |
(40.60) | (41.60) | (33.53) | (43.25) | |
Working Capital |
183.74 | 212.05 | 246.47 | 141.05 | |
Capital Expenditures |
(0.29) | — | 0.00 | 0.07 | |
Net Current Asset Value |
152.27 | 180.28 | 221.40 | 139.72 | |
| Other line items | |||||
Quick Ratio |
8.75 | 7.97 | 7.65 | 5.05 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.66) | (0.69) | (0.76) | (1.00) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
6.43 | 10.04 | 4.97 | 6.47 | |
Average Assets |
223.17 | 258.84 | 299.24 | 263.18 | |
Average Common Equity |
174.96 | 209.80 | 249.43 | 227.33 | |
Capex to Sales |
0.00 | — | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates